Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants.
Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants.
复制标题
DOI：
10.1126/sciimmunol.abn8014
复制
发表时间：
2022-02-18
影响因子：
24.8
通讯作者：
Tafesse FG
中科院分区：
文献类型：
--
作者：
Bates TA;McBride SK;Leier HC;Guzman G;Lyski ZL;Schoen D;Winders B;Lee JY;Lee DX;Messer WB;Curlin ME;Tafesse FG
目前的COVID-19疫苗显著降低了整体发病率和死亡率，对控制大流行至关重要。与未接种疫苗的同龄人相比，先前从COVID-19中康复的个体在接种疫苗后免疫应答增强（混合免疫）;然而，接种疫苗后突破性感染对体液免疫应答的影响仍有待确定。在这里，我们测量了104名接种疫苗的个体的中和抗体应答，包括那些具有突破性感染、混合免疫和无感染史的个体。我们发现，突破性感染后的人免疫血清和自然感染后的疫苗接种，广泛中和SARS-CoV-2变异到相似的程度。虽然年龄与单独接种疫苗后的抗体应答呈负相关，但在突破或混合免疫组中未发现与年龄的相关性。总之，我们的数据表明，来自自然感染的额外抗原暴露大大提高了体液免疫应答的数量、质量和广度，无论其发生在接种疫苗之前还是之后。SARS-CoV-2感染与疫苗接种相结合，无论这些事件的顺序如何，都可以类似地提高抗体质量。
Current COVID-19 vaccines significantly reduce overall morbidity and mortality and are vitally important to controlling the pandemic. Individuals who previously recovered from COVID-19 have enhanced immune responses after vaccination (hybrid immunity) compared to their naïve-vaccinated peers; however, the effects of post-vaccination breakthrough infections on humoral immune response remain to be determined. Here, we measure neutralizing antibody responses from 104 vaccinated individuals, including those with breakthrough infections, hybrid immunity, and no infection history. We find that human immune sera following breakthrough infection and vaccination following natural infection, broadly neutralize SARS-CoV-2 variants to a similar degree. While age negatively correlates with antibody response after vaccination alone, no correlation with age was found in breakthrough or hybrid immune groups. Together, our data suggest that the additional antigen exposure from natural infection substantially boosts the quantity, quality, and breadth of humoral immune response regardless of whether it occurs before or after vaccination. SARS-CoV-2 infection combined with vaccination improves antibody quality similarly regardless of the order of these events.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2110345
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Thomas SJ;Moreira ED Jr;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Polack FP;Zerbini C;Bailey R;Swanson KA;Xu X;Roychoudhury S;Koury K;Bouguermouh S;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Yang Q;Liberator P;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Gruber WC;Jansen KU;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s0140-6736(21)02183-8
发表时间：
2021-10-16
期刊：
Lancet (London, England)
影响因子：
--
作者：
Tartof SY;Slezak JM;Fischer H;Hong V;Ackerson BK;Ranasinghe ON;Frankland TB;Ogun OA;Zamparo JM;Gray S;Valluri SR;Pan K;Angulo FJ;Jodar L;McLaughlin JM
通讯作者：
McLaughlin JM
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G
影响因子：
16.6
作者：
Bates TA;Leier HC;Lyski ZL;McBride SK;Coulter FJ;Weinstein JB;Goodman JR;Lu Z;Siegel SAR;Sullivan P;Strnad M;Brunton AE;Lee DX;Adey AC;Bimber BN;O'Roak BJ;Curlin ME;Messer WB;Tafesse FG
通讯作者：
Tafesse FG